Lloyd A. Rowland, General Counsel at CytomX Therapeutics, Inc. (CTMX), bought 9,000 shares at $10.33 ($93K) on 2019-03-04, disclosed to the SEC on 2019-03-05.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| CTMX | SELL | 2024-03-21 | $11K | — | Filing → |
| CTMX | SELL | 2023-12-22 | $6K | — | Filing → |
| CTMX | SELL | 2023-09-22 | $7K | — | Filing → |